PeakData, a Zurich, Switzerland-based AI platform that identifies and collates the most relevant and impactful healthcare professionals (HCPs) for pharmaceutical companies, has announced a Series A funding round of €12.1 million (CHF 12 million).
AlbionVC led the round, with Octopus Ventures and Heal Capital also participating.
PeakData will use the funds to expand all aspects of the business to support its growth plans and to further develop the platform. In the next five years, the company hopes to have its platform used by the vast majority of pharmaceutical companies worldwide and in as many drug markets as possible.
Series A funding follows rapid 6x growth for the company over 2021.
Company: PeakData AG
Round: Series A
Funding Month: Aug 2022
Lead Investors: AlbionVC
Additional Investors: Octopus Ventures and Heal Capital
Company Website: https://www.peakdata.com/
Software Category: Agile targeting and segmentation SaaS platform
About the Company: Founded in 2018 by leading experts in Artificial Intelligence and Data Science, PeakData is a global AI company that uses swarms of AI to enhance commercial and medical effectiveness. Utilizing global and local data sources, PeakData offers HCP insights that help answer key questions in an easy-to-use web-based platform. Core service offerings include profiling and mapping, relationship and influence mapping, agile targeting, and segmentation, all of which are done in real time, to provide recent and actionable insights at scale. PeakData enables pharmaceutical companies to enhance the depth and breadth of their customer base and learn more about HCPs that are most relevant to their target market, and in turn, ensure patients benefit from innovative new medicines much sooner. PeakData has quickly grown, and currently has 70 employees, with offices in 5 countries and servicing more than 20 large pharma clients globally.